Cook KM, et al. - Researchers investigated if combination therapy with vancomycin and piperacillin–tazobactam (TZP) is associated with a higher incidence of acute kidney injury (AKI) in pediatric patients than those receiving combination therapy with vancomycin and cefepime. Among hospitalized children at their institution, the TZP group showed development of AKI almost 3 times sooner than the cefepime group. Type of combination therapy remained a significant predictor for AKI in multivariate conditional Poisson analysis in which adjustments were made for age, sex, use of concomitant nephrotoxins, and vancomycin dose.